Mastering Stable Angina Guidelines for SCE Cardiology Success

Introduction

Stable angina remains one of the most common presentations in cardiology practice, and a thorough understanding of its management is essential for success in the SCE Cardiology exam. This comprehensive guide covers the latest NICE guidelines and evidence-based approaches to diagnosing and managing stable angina, specifically tailored for SCE candidates.

Understanding Stable Angina

Stable angina is characterized by chest discomfort precipitated by physical exertion or emotional stress and relieved by rest or nitrates. It represents myocardial ischemia due to fixed coronary artery stenosis (>70% luminal narrowing).

Key Diagnostic Features

• Typical angina: Substernal chest pressure/pain triggered by exertion, lasting <10 minutes, relieved by rest or nitrates

• Atypical features: May include dyspnea, fatigue, or epigastric discomfort as presenting symptoms

• Non-cardiac chest pain: Pleuritic, positional, or sharp pain unlikely to be angina

Initial Assessment

According to NICE guidelines NG185, the initial assessment includes:

1. History and physical examination

2. 12-lead ECG (normal in up to 50% of patients)

3. Basic blood tests: Full blood count, lipids, HbA1c, renal function

4. Chest X-ray if suspected heart failure or alternative diagnosis

Investigating Stable Angina

Non-Invasive Functional Testing

For patients with typical or atypical angina:

Anatomical Assessment

CT coronary angiography (CTCA) is recommended as first-line investigation for patients with:

• Typical symptoms but low-intermediate pre-test probability

• Uninterpretable or equivocal functional tests

Invasive coronary angiography remains gold standard and is indicated when:

• Refractory symptoms despite medical therapy

• High-risk anatomy suspected

• Need for revascularization assessment

Medical Management Guidelines

First-Line Pharmacotherapy

Anti-ischemic medications:

1. Beta-blockers (first-line)

   • Metoprolol, bisoprolol, or atenolol

   • Titrate to resting heart rate 55-60 bpm

   • Avoid in severe bradycardia, hypotension, or acute decompensated HF

2. Calcium channel blockers (if beta-blockers contraindicated or insufficient)

   • Diltiazem or amlodipine

   • Avoid verapamil with beta-blockers (bradycardia risk)

   • Diltiazem caution in heart failure

3. Nitrates (short-acting for breakthrough symptoms)

   • GTN spray/sublingual tablets

   • Consider long-acting nitrates if frequent symptoms

   • 12-hour nitrate-free interval to prevent tolerance

Secondary Prevention

Antiplatelet therapy:

• Aspirin 75-100mg daily (unless contraindicated)

• Clopidogrel 75mg daily if aspirin intolerant

• Consider DAPT (aspirin + clopidogrel) post-PCI

Lipid lowering:

• High-intensity statin (atorvastatin 40-80mg, rosuvastatin 20-40mg)

• Aim for LDL-C <1.8mmol/L or >50% reduction

• Consider ezetimibe or PCSK9 inhibitors if target not met

Other cardioprotective medications:

• ACE inhibitor/ARB if hypertension, diabetes, or LVEF <40%

• SGLT2 inhibitors in patients with diabetes and cardiovascular disease

Risk Factor Modification

• Smoking cessation: Nicotine replacement, varenicline, bupropion

• Blood pressure control: Target <140/90mmHg

• Diabetes management: HbA1c <53mmol/mol (individualized)

• Weight management: BMI 20-25kg/m²

• Physical activity: At least 150 minutes moderate intensity weekly

Revascularization Considerations

PCI vs Medical Therapy

CABG indications:

• Left main stem disease

• Triple vessel disease (especially with diabetes/LV dysfunction)

• Complex bifurcation lesions

• Failed PCI

PCI indications:

• Single vessel disease or 2-vessel disease without proximal LAD involvement

• Technically suitable lesions

• Patient preference

Post-Revascularization Care

• Continue optimal medical therapy indefinitely

• Cardiac rehabilitation referral

• Regular follow-up for symptom monitoring

• Dual antiplatelet therapy duration based on stent type

SCE Exam High-Yield Points

1. NICE NG185 (2023): Updated guidance on chest pain assessment

2. ISCHEMIA trial: Medical therapy non-inferior to initial invasive strategy in stable CAD

3. FFR-guided PCI: Functional assessment reduces unnecessary interventions

4. Microvascular angina: Consider in patients with symptoms but normal coronaries

5. Coronary artery spasm: Diagnosis with provocation testing, treat with calcium channel blockers

Conclusion

Mastering stable angina management requires understanding both conservative and invasive treatment pathways. Focus on guideline-directed medical therapy as the foundation, with revascularization reserved for appropriate candidates. Review the latest NICE guidelines and recent trials to stay current for your SCE Cardiology examination.

Key Takeaway: Remember the mantra - "Start beta-blockers first, add CCB if needed, optimize secondary prevention, and reserve intervention for refractory cases or high-risk anatomy."